Search

Your search keyword '"Gjerdrum, Lise Mette Rahbek"' showing total 6 results
Start Over Author "Gjerdrum, Lise Mette Rahbek" Journal blood
6 results on '"Gjerdrum, Lise Mette Rahbek"'

1. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma

Author

Gluud, Maria, Pallesen, Emil M. H., Buus, Terkild B., Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Kamstrup, Maria R., Bzorek, Michael, Danielsen, Maria, Bech, Rikke, Monteiro, Madalena N., Blümel, Edda, Willerslev-Olsen, Andreas, Lykkebo-Valløe, Anders, Vadivel, Chella Krishna, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menne, Geisler, Carsten, Becker, Jürgen C., Koralov, Sergei B., Iversen, Lars, Litman, Thomas, Woetmann, Anders, and Ødum, Niels

Published
2023
Full Text
View/download PDF

2. Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Author

Sørensen, Anders Lindholm Lindholm, primary, Skov, Vibe, additional, Kjær, Lasse, additional, Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, additional, Larsen, Morten Kranker, additional, Nielsen, Claus, additional, Thomsen, Carsten, additional, Gjerdrum, Lise Mette Rahbek, additional, Knudsen, Trine Alma, additional, Ellervik, Christina, additional, Overgaard, Ulrik Malthe, additional, Andersen, Christen Lykkegaard, additional, Bjørn, Mads Emil, additional, and Hasselbalch, Hans Carl, additional

Published
2022
Full Text
View/download PDF

3. The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

Author

Szabo, Agoston Gyula, primary, Thorsen, Jonathan, additional, Iversen, Katrine Fladeland, additional, Levring, Mette Bøegh, additional, Preiss, Birgitte, additional, Helleberg, Carsten, additional, Breinholt, Marie Fredslund, additional, Hermansen, Emil, additional, Gjerdrum, Lise Mette Rahbek, additional, Bønløkke, Søren, additional, Nielsen, Katrine, additional, Kjeldsen, Eigil, additional, Teodorescu, Manuela, additional, Dokhi, Marveh, additional, Kurt, Eva, additional, Strandholdt, Casper Noergaard, additional, Andersen, Mette Klarskov, additional, and Vangsted, Annette J., additional

Published
2021
Full Text
View/download PDF

6. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma

Author

Gluud, Maria, Pallesen, Emil M.H., Buus, Terkild B., Gjerdrum, Lise Mette Rahbek, Lindahl, Lise M., Kamstrup, Maria R., Bzorek, Michael, Danielsen, Maria, Bech, Rikke, Monteiro, Madalena N., Blümel, Edda, Willerslev-Olsen, Andreas, Lykkebo-Valløe, Anders, Vadivel, Chella Krishna, Krejsgaard, Thorbjørn, Bonefeld, Charlotte Menne, Geisler, Carsten, Becker, Jürgen C., Koralov, Sergei B., Iversen, Lars, Litman, Thomas, Woetmann, Anders, and Ødum, Niels

Abstract

Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results